Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Analtram is a combination analgesic product developed and marketed by Lapi Laboratories. It consists of two active ingredients: tramadol, a centrally acting synthetic opioid analgesic, and paracetamol (acetaminophen), a non-opioid analgesic and antipyretic. The drug is indicated for the management of moderate to severe pain. Tramadol provides pain relief through mu-opioid receptor agonism and the inhibition of the reuptake of norepinephrine and serotonin, while paracetamol provides additional analgesia likely through the inhibition of prostaglandin synthesis in the central nervous system. This combination allows for a synergistic effect, potentially providing superior pain relief compared to either component alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Analtram.